Rightslink® by Copyright Clearance Center

Paclitaxel and bevacizumab with or without capecitabine as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: A multicentre, open-label, randomised phase 2 trial

Author:

S.W. Lam,S.M. de Groot,A.H. Honkoop,A. Jager,A.J. ten Tije,M.M.E.M. Bos,S.C. Linn,J. van den Bosch,J.R. Kroep,J.J. Braun,H. van Tinteren,E. Boven

Publication:

European Journal of Cancer

Publisher:

Elsevier

Date:

December 2014

Please select your organization and/or account

Organization

Account

Please select your account from the above dropdown list. These accounts represent the offices, campuses, and other sites where your organization operates. Your account selection should match where you typically have an office or workspace. Even when you are traveling or temporarily working elsewhere, you should select the account that represents where you customarily work.

Cancel OK

Creative Commons

This is an open access article distributed under the terms of the license, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

You are not required to obtain permission to reuse this article.